Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H2 2012

Publisher Name :
Date: 31-Oct-2012
No. of pages: 128
Inquire Before Buying

Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS). Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Relapsing Remitting Multiple Sclerosis (RRMS).
- A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Relapsing Remitting Multiple Sclerosis (RRMS) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Relapsing Remitting Multiple Sclerosis (RRMS) Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) 11
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics under Development by Companies 13
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Pre-Clinical Stage Products 21
Comparative Analysis 21
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Products under Development by Companies 22
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Development 24
F. Hoffmann-La Roche Ltd. 24
Abbott Laboratories 25
Biogen Idec Inc. 26
Eli Lilly and Company 27
GlaxoSmithKline plc 28
MedImmune LLC 29
XenoPort, Inc. 30
Actelion Ltd 31
Ono Pharmaceutical Co., Ltd. 32
Teva Pharmaceutical Industries Limited 33
Genmab A/S 34
Momenta Pharmaceuticals, Inc. 35
Opexa Therapeutics, Inc. 36
Allozyne, Inc. 37
Adeona Pharmaceuticals, Inc. 38
Receptos, Inc. 39
Synthon BV 40
Celtaxsys, Inc. 41
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
laquinimod sodium - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
laquinimod sodium - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
tabalumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
daclizumab - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
firategrast - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ponesimod - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
PEGylated Interferon Beta-1A - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
estriol - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Tcelna - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MEDI-551 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ONO-4641 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
recombinant IFN Beta-1b - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
dimethyl fumarate - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Ocrelizumab + Methylprednisolone - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
ofatumumab - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Epigallocatechin Gallate - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
AZ-01 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Memantine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Interferon beta 1b + Atorvastatin - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
abatacept - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
XP-23829 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
RPC-1063 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
alemtuzumab - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
NT-KO-003 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Peptide-Coupled Peripheral Blood Mononuclear Cells - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Trimesta + Norethindrone - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Glatiramer Acetate - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
CTX-4398 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
BG-12 + Interferon Beta - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
T Cell Vaccination - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Boswellic Acids - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
BG-12 + Glatiramer Acetate - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Drug Profile Updates 96
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Dormant Products 115
Relapsing Remitting Multiple Sclerosis (RRMS) - Product Development Milestones 116
Featured News & Press Releases 116
Oct 04, 2012: XenoPort Reports Favorable Metabolism And Pharmacokinetics Of XP23829 In Phase I Trial 116
Sep 19, 2012: Biogen Idec Announces Publication Of Results From Two Phase III Trials Of Oral BG-12 In New England Journal Of Medicine 117
Aug 08, 2012: Teva To Initiate Third Phase III Trial Of Oral Laquinimod For Treatment Of Relapsing Remitting Multiple Sclerosis 119
Jul 23, 2012: XenoPort Initiates Phase I Study For Potential Treatment Of Multiple Sclerosis And Psoriasis 119
Jul 17, 2012: European Medicines Agency Accepts Start Of Scientific Review Of Marketing Authorization Application For Active Biotech's Laquinimod In Relapsing-Remitting Multiple Sclerosis 120
Jul 16, 2012: Enzon Presents Pre-Clinical Data On Controlled Release Of PEGylated Interferon-Beta-1b And PEGylated Anti-TNF-a Antibody Fragment 120
May 31, 2012: Novartis Announces Data From Phase III Gilenya Study For Treatment Of Relapsing-Remitting Multiple Sclerosis 121
May 24, 2012: XenoPort Submits Investigational New Drug Application For XP23829 As Potential Treatment Of RRMS 122
May 14, 2012: Biogen Idec's AVONEX Dosing Innovations For Treatment Of Multiple Sclerosis Now Available in US 123
Apr 26, 2012: Biogen And Elan Highlight New Data Of TYSABRI At AAN Annual Meeting 124
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 128
Disclaimer 128

List of Tables
Number of Products Under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H2 2012 11
Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Comparative Analysis by Late Stage Development, H2 2012 18
Comparative Analysis by Mid Clinical Stage Development, H2 2012 19
Comparative Analysis by Early Clinical Stage Development, H2 2012 20
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 23
F. Hoffmann-La Roche Ltd., H2 2012 24
Abbott Laboratories, H2 2012 25
Biogen Idec Inc., H2 2012 26
Eli Lilly and Company, H2 2012 27
GlaxoSmithKline plc, H2 2012 28
MedImmune LLC, H2 2012 29
XenoPort, Inc., H2 2012 30
Actelion Ltd, H2 2012 31
Ono Pharmaceutical Co., Ltd., H2 2012 32
Teva Pharmaceutical Industries Limited, H2 2012 33
Genmab A/S, H2 2012 34
Momenta Pharmaceuticals, Inc., H2 2012 35
Opexa Therapeutics, Inc., H2 2012 36
Allozyne, Inc., H2 2012 37
Adeona Pharmaceuticals, Inc., H2 2012 38
Receptos, Inc., H2 2012 39
Synthon BV, H2 2012 40
Celtaxsys, Inc., H2 2012 41
Assessment by Monotherapy Products, H2 2012 42
Assessment by Combination Products, H2 2012 43
Assessment by Stage and Route of Administration, H2 2012 45
Assessment by Stage and Molecule Type, H2 2012 47
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Drug Profile Updates 96
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Dormant Products 115

List of Figures
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H2 2012 11
Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 18
Mid Clinical Stage Products, H2 2012 19
Early Clinical Stage Products, H2 2012 20
Pre-Clinical Stage Products, H2 2012 21
Assessment by Monotherapy Products, H2 2012 42
Assessment by Combination Products, H2 2012 43
Assessment by Route of Administration, H2 2012 44
Assessment by Stage and Route of Administration, H2 2012 45
Assessment by Molecule Type, H2 2012 46
Assessment by Stage and Molecule Type, H2 2012 47

  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Growth in the Indian Watch Industry
    Earlier, in India watches were seen as a luxury item. However, watches are now witnessing a fundamental change in perception, and are now gaining respect as an essential utility item. With the liberalization of the Indian market, coupled with the rising purchasing power of the young and consumerist Indians, watch industry in India seems to [...]
  • Global Retail Ready Packaging Market to Witness Steady Growth
    The market for retail ready packaging has witnessed impressive growth in recent years with boom in the retail industry. Retail ready packaging, also known as shelf-ready packaging is designed for the retail outlet, ready to be placed on shelf without any need for unpacking or repacking. In 2011, the global market for retail packaging was [...]
  • Flow Cytometry Market by Technology (Cell & Bead-based), Products & Services (Reagents, Instruments, Software, & Accessories), Application (Research & Clinical), End User (Commercial Organizations & Diagnostics Laboratories) – Global Forecasts to 2018
    Published: 17-Apr-2014        Price: US $4650 Onwards        Pages: 270
    The global flow cytometry market is estimated to grow at a lower CAGR in developed countries; however it is expected to witness a high growth in the emerging countries such as China, India, and Brazil. Factors such as the technological advancements in flow cytometry instruments; fostering research activities in the field of life sciences such as proteomics, genomics, and pharmacogenomics; growing clinical trials; fostering prevalence of HIV and cancer; launch of new reagents for specific applica......
  • Food Diagnostics Systems Market [By Type (Hybridization, Chromatography, Spectrometry, Biosensor, Immunoassay, Testing Kit)], Consumables Market [By Type (Reagents, Disinfectants, Test Accessories)] & By Geography – Global Trends & Forecast To 2018
    Published: 16-Apr-2014        Price: US $4650 Onwards        Pages: 290
    The food diagnostics market size is projected to increase with rising concerns over food quality and safety, and the implementation of stringent regulations on food safety and foodborne illness prevention. Globalization of food trade has further extended the scope for the food diagnostics market. The emerging markets with increasing demand for food testing are estimated to generate potential opportunities in the market. The food diagnostics market was sub-segmented into diagnostic systems and......
  • 2014 Deep Research Report on Global and China H acid Industry
    Published: 16-Apr-2014        Price: US $2200 Onwards        Pages: 149
    This is a professional and depth research report on Global and China H acid industry. The report firstly introduced H acid basic information included H acid definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, H acid industry policy and plan, H acid product specification, manufacturing process, product cost structure etc. then statis......
  • Fluid Management & Visualization Systems Market by Product (Suction & Irrigation, Dialyzer, Fluid Warming & Waste Management, Endoscopic Camera, Tubing’s, Bloodlines), & Application (GI, Urology, Arthroscopy, Gynecology) – Global Forecasts to 2018
    Published: 16-Apr-2014        Price: US $4650 Onwards        Pages: 360
    The fluid management and visualization systems industry has evolved from traditional standalone systems to modern automated, integrated systems to increase the endosurgical procedure outcomes. Patient safety and security from infections have also gained greater importance in fluid management and visualization systems over the years. Over the past few years, the fluid management and visualization systems market has witnessed a stable growth. The market is expected to grow at a CAGR of 6.1% fro......
  • Bahrain Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 101
    BMI View: This quarter has seen the beginning of a multi-phased plan by the National Health Regulatory Authority to significantly reduce medicine prices in the country, signalling a potential advancement towards the implementation of a unified Gulf Cooperation Council pricing system. Although less optimistic than before, our medium- and long-term outlooks for the Bahrain pharmaceutical market remain bullish. Medicines uptake will be supported by robust economic growth, in addition to the country......
  • Cambodia and Laos Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 65
    BMI View: Low health and pharmaceutical expenditures will continue to limit the attractiveness of the pharmaceutical market in Cambodia. Given such a profile, the country will present more commercial benefits to companies dealing with inexpensive generic drugs and over-the-counter products than innovative pharmaceuticals. Headline Expenditure Projections ? Pharmaceuticals: KHR828.7bn (US$210mn) in 2013 to KHR921.9bn (US$230mn) in 2014; +11.2% in local currency terms and +11.8% in US dollar terms......
  • Czech Republic Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 104
    BMI View: Overall, the Czech healthcare system is facing severe challenges as it struggles to contain budget deficits. At the same time, demand for the latest pharmaceuticals and access to healthcare services is expected to continue its steady growth trajectory, putting pressure on the state and insurers to raise premiums or redistribute funding. Following the release of pharmaceutical sales data by the SUKL, we have significantly revised down historical values for 2013 and forecasts from 2014 o......
  • Denmark Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 60
    BMI View: Although Denmark's pharmaceutical market is relatively small compared to other Western European countries, the demand for high quality healthcare will remain elevated by an increasing and ageing population. This demand could provide opportunities for private healthcare providers to expand as the government continues its restructuring and cost containment measures across the public healthcare sector. Headline Expenditure Projections ? Pharmaceuticals: DKK20.20bn (US$3.58bn) in 2013 to D......
  • Iraq Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 75
    BMI View: The projected growth of Iraq's pharmaceutical market in 2014 and 2015 is linked to an oildriven economic expansion, which is dependent on the government's ability to represent and appease the country's factions. Given the government's expansionary fiscal policy, spending on education, health and public services will be elevated over the coming quarters. In particular, Baghdad will seek to modernise healthcare provision, in a view to improve support to its rule. Nevertheless, there are ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs